Cargando…
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
BACKGROUND: PD-L1 expression and tumour mutational burden (TMB) are both associated with the responses of multiple tumours to immune checkpoint inhibitor (ICI) therapy. However, their prevalence and correlations may differ in different types of advanced solid tumours. METHODS: PD-L1 expression, TMB,...
Autores principales: | Chen, Yanhui, Wang, Yating, Luo, Hongli, Meng, Xue, Zhu, Wei, Wang, Di, Zeng, Hui, Zhang, Henghui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397649/ https://www.ncbi.nlm.nih.gov/pubmed/32775040 http://dx.doi.org/10.1186/s40164-020-00173-3 |
Ejemplares similares
-
Estimating the Frequency of Single Point Driver Mutations across Common Solid Tumours
por: Darbyshire, Madeleine, et al.
Publicado: (2019) -
PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer
por: Chen, Yanhui, et al.
Publicado: (2019) -
Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples
por: Mankor, Joanne M., et al.
Publicado: (2020) -
Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer
por: Zhang, Libin, et al.
Publicado: (2021) -
Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis
por: Xiang, Xuemei, et al.
Publicado: (2022)